These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft. McClelland J; Wong E; Grigg A Leuk Lymphoma; 2023 Feb; 64(2):440-444. PubMed ID: 36368718 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan. Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883 [TBL] [Abstract][Full Text] [Related]
10. The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. Collins J; Shea K; Parsad S; Plach K; Lee P J Oncol Pharm Pract; 2020 Jan; 26(1):5-12. PubMed ID: 30854922 [TBL] [Abstract][Full Text] [Related]
11. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329 [TBL] [Abstract][Full Text] [Related]
13. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530 [TBL] [Abstract][Full Text] [Related]
14. Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. Heinz WJ; Cabanillas Stanchi KM; Klinker H; Blume O; Feucht J; Hartmann U; Feuchtinger T; Lang P; Handgretinger R; Döring M Med Mycol; 2016 Feb; 54(2):128-37. PubMed ID: 26483433 [TBL] [Abstract][Full Text] [Related]
15. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424 [TBL] [Abstract][Full Text] [Related]
16. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients. Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of posaconazole tablets versus fluconazole as prophylaxis for invasive fungal diseases in patients with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Grau S; Cámara R; Jurado M; Sanz J; Aragón B; Gozalbo I Eur J Health Econ; 2018 May; 19(4):627-636. PubMed ID: 28569350 [TBL] [Abstract][Full Text] [Related]